10-Q: Harmony Biosciences Reports Q2 2024 Results, Revenue Growth Driven by Increased WAKIX Sales

Harmony Biosciences reported a 28.8% increase in net product revenue for the second quarter of 2024, driven by higher sales volume of WAKIX and a price increase.

Summary

• Harmony Biosciences reported a net product revenue of $172.8 million for the three months ended June 30, 2024, a 28.8% increase compared to the same period in 2023.
• The increase in revenue was primarily due to a 24.1% increase in units shipped and a 7% price increase, partially offset by higher rebates and co-pay assistance.
• Cost of product sales increased by 28.5% to $32.1 million for the quarter, while research and development expenses surged by 324.8% to $63.6 million due to IPR&D charges and increased clinical program costs.
• Sales and marketing expenses rose by 16.2% to $28.5 million, and general and administrative expenses increased by 19.4% to $27.2 million.
• The company reported a net income of $11.6 million for the quarter, a decrease from $34.3 million in the same period last year, primarily due to increased operating expenses.
• For the six months ended June 30, 2024, net product revenue was $327.4 million, a 29.2% increase year-over-year, with a net income of $49.9 million.
• The company had cash, cash equivalents, and investments of $434.1 million as of June 30, 2024, and outstanding debt of $188.8 million.
• Harmony Biosciences believes its current cash and investments will meet its operational liquidity needs for the next 12 months.

Sentiment

Score: 6

Explanation: The document shows strong revenue growth and pipeline expansion, but the significant increase in R&D expenses and decrease in net income temper the overall positive outlook. The ongoing patent litigation also adds a layer of uncertainty.

Positives

• The company experienced strong revenue growth driven by increased sales of WAKIX.
• Harmony Biosciences has secured broad formulary access for WAKIX, covering over 80% of insured lives in the U.S.
• The company has a robust pipeline with ongoing clinical trials for additional indications of pitolisant and other acquired assets.
• The FDA approval of WAKIX for pediatric narcolepsy expands the market reach of the drug.
• The company has a strong cash position and believes it can meet its operational liquidity needs for the next 12 months.

Negatives

• Net income decreased significantly compared to the same period last year due to increased operating expenses.
• Research and development expenses increased substantially due to IPR&D charges and increased clinical program costs.
• The company is facing patent litigation related to generic versions of WAKIX.

Risks

• The company faces risks related to clinical trial outcomes, regulatory approvals, and competition from other pharmaceutical companies.
• There is a risk of fluctuations in sales discounts and allowances, which could impact net revenue.
• The company is dependent on a single supplier for its product and active pharmaceutical ingredient.
• The company is involved in patent litigation that could impact its revenue and market position.
• The company's future success depends on the successful development and commercialization of its product candidates.

Future Outlook

The company plans to submit a supplemental NDA (sNDA) for idiopathic hypersomnia (IH) in the second half of 2024 based on the totality of data from the INTUNE study and other sources. They also plan to file an IND in mid-2025 and begin first-in-human studies for an orexin-2 receptor agonist (OX2R) in the second half of 2025. The company anticipates topline data from the Phase 3 RECONNECT study for ZYN002 in mid-2025.

Management Comments

• The company believes that pitolisant's ability to regulate histamine gives it the potential to provide therapeutic benefit in other rare neurological diseases.
• Management is focusing development efforts on other rare neurological disorders in which EDS is a prominent symptom, including Prader-Willi Syndrome (PWS) and myotonic dystrophy (DM).
• The company seeks to expand its pipeline through the acquisition of additional assets that focus on addressing the unmet needs of patients living with rare neurological diseases.

Industry Context

The company operates in the pharmaceutical industry, specifically focusing on rare neurological disorders. The approval of WAKIX for pediatric narcolepsy aligns with the industry trend of expanding treatment options for underserved patient populations. The acquisition of Zynerba and Epygenix demonstrates a strategy of diversifying the pipeline through acquisitions, which is a common practice in the pharmaceutical sector.

Comparison to Industry Standards

• Harmony's revenue growth of 28.8% in Q2 2024 is strong compared to the average growth rate of many established pharmaceutical companies, but is not unusual for a company with a relatively new product in the market.
• The significant increase in R&D spending reflects the company's commitment to expanding its pipeline, which is typical for biotech companies in the growth phase.
• The company's focus on rare diseases aligns with a growing trend in the pharmaceutical industry, where companies are increasingly targeting niche markets with high unmet needs.
• The company's cash position of $434.1 million is relatively strong, providing a solid foundation for future growth and acquisitions, similar to other well-funded biotech companies.
• The patent litigation faced by Harmony is not uncommon in the pharmaceutical industry, where generic competition is a constant threat to branded products. Companies like Teva, Mylan, and Viatris have faced similar challenges.

Legal Proceedings

• The company is involved in patent litigation with Lupin, Novugen, Novitium, Zenara, AET, Annora, and MSN related to generic versions of WAKIX.

Related Party Transactions

• The company has a right-of-use agreement with Paragon Biosciences, LLC, for office space in Chicago, Illinois.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income despite strong revenue growth.
• Employees may benefit from the company's growth and expansion.
• Patients may benefit from the development of new treatments for rare neurological disorders.
• Customers (specialty pharmaceutical distribution companies) will continue to be key partners in the commercialization of WAKIX.
• Suppliers will see increased demand as the company expands its production.

Next Steps

• The company plans to submit a supplemental NDA (sNDA) for idiopathic hypersomnia (IH) in the second half of 2024.
• The company plans to file an IND in mid-2025 and begin first-in-human studies for an orexin-2 receptor agonist (OX2R) in the second half of 2025.
• The company anticipates topline data from the Phase 3 RECONNECT study for ZYN002 in mid-2025.
• The company will continue to advance its clinical programs for pitolisant in PWS and DM.
• The company will continue to pursue additional acquisitions to expand its pipeline.

Key Dates

Keywords

WAKIX, pitolisant, narcolepsy, idiopathic hypersomnia, Prader-Willi Syndrome, myotonic dystrophy, ZYN002, Fragile X Syndrome, clemizole, Dravet Syndrome, Lennox-Gastaut Syndrome, clinical trials, FDA approval, pharmaceutical, biotechnology